Hematologist in Sao Paulo, Brazil. Focus on Lymphomas and CLL Host: Fase 3 Podcast Host: Happy Auer Podcast
Sao Paulo, Brazil
Joined August 2020
- Tweets2.9K
- Following2.8K
- Followers3.4K
- Likes4.5K
Pinned Tweet
You have to be always drunk. That's all there is to it; it's the only way. So as not to feel the horrible burden of time that breaks your back and bends you to the earth, you have to be continually drunk.
But on what? Wine, poetry or virtue, as you wish. But be drunk
Baudelaire
Guilherme Perini, MD retweeted
Impact of healthcare setting on survival in adults with acute lymphoblastic leukemia in Latin America: insights from a large multinational cohort - The Lancet Regional Health – Americas thelancet.com/journals/lanam… 🇦🇷🇧🇷🇨🇱
Guilherme Perini, MD retweeted
On the 3rd anniversary of October 7, it’s important to remember the full hideous horror of what Hamas did that day to the Israeli people - and to condemn it, unequivocally.
Those who still refuse to condemn it are complicit in supporting terrorism.
Guilherme Perini, MD retweeted
Review: N-AVD or BrECADD for Advanced-Stage Classical Hodgkin Lymphoma: Choosing the Right Treatment for the Right Patient
clinical-lymphoma-myeloma-le…
Yes, but lets not forget that the RR scenario is in constant improvement.
Might take years for an OS benefit.
I think if the difference in PFS remains in longer follow ups, we have a winner!
HR 0.49 certainly has my attention. But before we "CHOP" R-CHOP from the frontline, I want to know we’re actually curing more patients.
Frontline DLBCL is curative. My bar for adding a bispecific to R-CHOP is higher than improving PFS alone. Show me the curves. Show me the toxicity. Show me the OS.
PFS gets my attention. OS changes my practice.
Ok, looks like Epco-R-CHOP is ready for primetime.
HR 0.49 is impressive, and will probably be the new SoC.
What we eagerly wait:
1. Toxicity data
2. How Glofi-Pola-R-CHP will perform in the ph3 trial
3. Molecular data
Exciting times ahead!
Guilherme Perini, MD retweeted
This should be pushed far and wide. Watched in every college class in the U.S. Thank you @billmaher The moral confusion is gross. "It is not a genocide, it is a counterattack in a war...Gaza equals genocide is a lie, an easily provable lie (as I have argued from first hand observations in Gaza). The fact that so many democrats go along with it is to me the party's worse moment since they undid reconstruction after the civil war...words have meaning...genocide, kill or try to kill an entire people, you can't just change the definition of genocide to mean counterattack in a war where people including civilians die, that's every war..."
If Anthracycline is Key, why should we celebrate a regimen that has lower dosis of Doxo compared to the ABVD backbone?
Let the war begins...
New paper alert 👀 thank you to @Haematologica for publishing our analysis of ~30,000 UK classic Hodgkin lymphoma patients, with a focus on the ever-interesting older population. NB: anthracycline is key! haematologica.org/article/vi… @DavidJCutter @graham74GC
Para surpresa de zero pessoas.
Os caras sao lendas vivas.
Crítica: Roupa Nova e Guilherme Arantes fazem um dos melhores shows do Rock in Rio 2026
oglobo.globo.com/cultura/mus…
This might be the most non-sense idea I have ever read.
Whats next?
Abandon talking to patients?
A call to abandon performative physical examinations. Join me?
Physical Examination for Asymptomatic Adults | New England Journal of Medicine nejm.org/doi/full/10.1056/NE…
We only transplant what we dont know how to treat.
🤔🤔🤔🤔🤔
Ibrutinib versus allogeneic haematopoietic stem cell transplant in relapsed/refractory del(17p) chronic lymphocytic leukaemia/small lymphocytic lymphoma onlinelibrary.wiley.com/doi/… #CLL #leusm
I had the opportunity to share a session on DLBCL with Dr. Vitolo. A true honor.
And I had the opportunity to ask him about CNS prophylaxis in testicular lymphoma!
2y-PFS of 80% in a ph2 will probably be a little bit less in the ph3.
Will it be practice changing?
Im still trying to digest all data.
Fixed-duration epcoritamab plus R-CHOP in newly diagnosed LBCL with IPI score 3-5: results from the EPCORE NHL-2 trial ashpublications.org/blood/ar…
Guilherme Perini, MD retweeted
🚨 our multiregional expert consensus report on treatment selection in chronic lymphocytic leukemia (CLL) has just been published online in Blood Global Hematology 🤓🙌
#CLLsm
@BloodPortfolio @ASH_hematology
sciencedirect.com/science/ar…
I am truly honoured to be first author in a ROW consensus on CLL treatment.
I am forever thankful for the great discussions from colleagues from so many places in the world.
Hope you guys enjoy it.
Guilherme Perini, MD retweeted
✨️ BJHaem Editor's pick - August ✨️
Ibrutinib plus venetoclax for relapsed/refractory mantle cell lymphoma: Final analysis of the phase 3 SYMPATICO study
buff.ly/o6Uijaw
Congratulations to @michaelwangmd and collegues on this distinction!
@DrAEvens | @WileyHealth
Guilherme Perini, MD retweeted
Cómo se informan las decisiones en Hematología y el rol de la evidencia del mundo real en esta segunda entrega de Hematology Sin Filtros
¿Cómo tomamos decisiones en hematología? Entre ensayos clínicos aleatorizados, datos del mundo real y la incertidumbre de la práctica diaria, ¿cómo integramos la evidencia para tomar las mejores decisiones terapéuticas para nuestros pacientes?
#HealthcareUnfiltered & #FASE3
Guilherme Perini, MD retweeted
¿Cómo tomamos decisiones en hematología? Entre ensayos clínicos aleatorizados, datos del mundo real y la incertidumbre de la práctica diaria, ¿cómo integramos la evidencia para tomar las mejores decisiones terapéuticas para nuestros pacientes?
#HealthcareUnfiltered & #FASE3
Guilherme Perini, MD retweeted
¿Cómo tomamos decisiones en hematología? Entre ensayos clínicos, datos del mundo real y la incertidumbre de la práctica diaria, ¿cómo integramos la evidencia para elegir el mejor tratamiento para cada paciente? Nuevo episodio este lunes.
#HealthcareUnfiltered
Pls share/subscribe
